Navigation Links
Sagent Pharmaceuticals Launches Ciprofloxacin Injection, USP, 5% Dextrose Premix Bag
Date:3/19/2008

SCHAUMBURG, Ill., March 19 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company today announced that it has launched ciprofloxacin injection, USP, 5% dextrose premix bag, a synthetic broad spectrum antimicrobial agent for intravenous (I.V.) administration used to treat bacterial infections. Sagent's ciprofloxacin injection will be available immediately in 200mg and 400mg premix bags. According to IMS data, sales of injectable ciprofloxacin in the United States in 2006 were approximately $60 million.

"We are poised to be one of the first companies to make the I.V. form of this important antibiotic widely available to patients in the U.S.," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "The launch of our ciprofloxacin -- in ready-to-use, customer friendly, barcoded I.V. bags -- simultaneous with the expiry of the innovator's patent exclusivity further demonstrates Sagent's capabilities and expertise in injectable pharmaceutical products and our seasoned management team's commitment to the needs of patients and customers."

Ciprofloxacin is the third product introduced from Sagent's pipeline of more than 200 products since the launch of the company's first product, adenosine injection, USP, in December 2007. Earlier this month, the company launched another antibiotic, cefazolin for injection, USP, which is available in 1g single dose vials and 10g pharmacy bulk package vials.

About Ciprofloxacin

Ciprofloxacin injection, USP, is a synthetic broad spectrum antimicrobial agent for intravenous administration used to treat a variety of infections and is the generic equivalent of Bayer Pharmaceuticals' CIPRO(R) I.V. Ciprofloxacin belongs to the fluoroquinolone family of drugs. Ciprofloxacin injection, USP, is indicated for infections of the urinary tract, skin and skin structure, bones and joints, as well as nosocomial pneumonia, acute sinusitis, chronic bacterial prostatitits, lower respiratory infections and complicated intra-abdominal infections. In addition, ciprofloxacin can be effective in reducing the incidence or progression of inhalational anthrax following exposure to the bacteria. The most common adverse effects may include nausea, vomiting, dizziness or drowsiness, blurred vision, insomnia, joint stiffness or muscle pain or photosensitivity. Less common adverse effects include seizure, psychological episodes, jaundice, diarrhea, numbness or tingling, or chest pain or palpitations. Rarely, ciprofloxacin can cause joint damage, including tendon rupture.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of

pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit http://www.SagentPharma.com.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Sagent Pharmaceuticals Inc. Completes $53 Million Series A Financing
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... In ... Heart Failure Nurses (AAHFN) is promoting healthier living with heart failure by providing ... Life! Healthy Living with Heart Failure will kick-off February 14 and includes tips ...
(Date:2/13/2016)... (PRWEB) , ... February 13, 2016 , ... Many individuals ... of protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved ... it once more, but without the high-carb repercussions. IsoPasta has 30 grams of ...
(Date:2/13/2016)... ... ... an Au Pair comes all the way around the world to provide child ... are often worried things won’t go well. More often than not, however, they find out ... the Year winner’s all commented how their Au Pairs have become a part of the ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, Morrow, Ryan & ... purpose of these scholarships is to encourage applicants to pursue a degree in their ... these two parishes. , “We have available jobs in St. Landry and Evangeline ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical Therapy ... Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the country ... in action, learn more about their chosen field and network with their colleagues. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... birth tissues, human skin and bone, and patent-protected processes ... and therapies, announced today that it will present at ... New York , NY.  Parker H. ... , Chief Financial Officer and Chris Cashman , ...
(Date:2/11/2016)... WESTPORT, Conn. , Feb. 11, 2016  AfterPill.com ... decision to recommend alcohol abstinence for all women who ... women in the U.S. each year and raises the ... --> --> According to the ... U.S., 70% of women of child-bearing age, who have ...
(Date:2/11/2016)... Feb. 11, 2016 Wearable posture tracker, ALEX , has taken Kickstarter by storm, crowdfunding ... seven days left to go, ALEX is said to be delivered to backers starting May of this ... ... ... Created by NAMU, a ...
Breaking Medicine Technology: